ES2282062T1 - Composicion farmaceutica que contiene irbesartan. - Google Patents
Composicion farmaceutica que contiene irbesartan. Download PDFInfo
- Publication number
- ES2282062T1 ES2282062T1 ES05775601T ES05775601T ES2282062T1 ES 2282062 T1 ES2282062 T1 ES 2282062T1 ES 05775601 T ES05775601 T ES 05775601T ES 05775601 T ES05775601 T ES 05775601T ES 2282062 T1 ES2282062 T1 ES 2282062T1
- Authority
- ES
- Spain
- Prior art keywords
- approximately
- composition according
- composition
- irbesartan
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Composición que comprende más del 70% de irbesartán p/p y por lo menos un excipiente farmacéuticamente aceptable.
Claims (40)
1. Composición que comprende más del 70% de
irbesartán p/p y por lo menos un excipiente farmacéuticamente
aceptable.
2. Composición según la reivindicación 1, que
presenta un perfil de disolución según el cual más de
aproximadamente el 85% del irbesartán está disuelto en
aproximadamente 30 minutos utilizando el aparato 2 de USP, colocando
el comprimido en 1000 ml de ácido clorhídrico 0,1 N a 37ºC con una
velocidad del agitador de 50 rpm.
3. Composición que comprende más del 70% de
irbesartán, en la que dicha composición presenta un perfil de
disolución según el cual más de aproximadamente el 85% del
irbesartán está disuelto en aproximadamente 30 minutos utilizando
el aparato 2 de USP, colocando el comprimido en 1000 ml de ácido
clorhídrico 0,1 N a 37ºC con una velocidad del agitador de 50
rpm.
4. Composición según la reivindicación 3, que
comprende más del 75% p/p de irbesartán y por lo menos un
excipiente farmacéuticamente
aceptable.
aceptable.
5. Composición según cualquiera de las
reivindicaciones 1 a 4, en forma de comprimido.
6. Composición según cualquiera de las
reivindicaciones 1 a 5, en la que dicha composición comprende un
aglutinante.
7. Composición según la reivindicación 6, en
la que el aglutinante es povidona o almidón pregelatinizado.
8. Composición según la reivindicación 7, en
la que el aglutinante es povidona.
9. Composición según la reivindicación 8, en
la que la povidona está comprendida entre aproximadamente 1,0 y
aproximadamente 7,0% p/p de la composición.
10. Composición según cualquiera de las
reivindicaciones 6 a 9, en la que un aglutinante es almidón
pregelatinizado (almidón 1500).
11. Composición según la reivindicación 10, en
la que el almidón pregelatinizado (almidón 1500) está comprendido
entre aproximadamente 1,0 y aproximadamente 10,0% p/p de la
composición.
12. Composición según cualquiera de las
reivindicaciones 1 a 11, en la que dicha composición comprende un
disgregador.
13. Composición según la reivindicación 12, en
la que un disgregador es la croscarmelosa sódica.
14. Composición según la reivindicación 13, en
la que la croscarmelosa sódica es
Ac-Di-Sol y está comprendida entre
aproximadamente el 1,0% y aproximadamente el 7,0% p/p de la
composición.
15. Composición según cualquiera de las
reivindicaciones 1 a 14, en la que dicha composición comprende un
tensioactivo.
16. Composición según la reivindicación 15, en
la que dicho tensioactivo es poloxámero 188.
17. Composición según la reivindicación 16, en
la que el poloxámero 188 está comprendido aproximadamente entre el
0,2 y aproximadamente el 6,0% p/p de la composición.
18. Composición según cualquiera de las
reivindicaciones 1 a 17, en la que dicha composición comprende un
diluyente.
19. Composición según la reivindicación 18, en
la que dicho diluyente es celulosa microcristalina.
20. Composición según la reivindicación 19, en
la que la celulosa microcristalina es Avicel PH 102 FMC y comprende
entre aproximadamente el 2,0 y aproximadamente el 10,0% p/p de la
composición.
21. Composición según cualquiera de las
reivindicaciones 1 a 20, en la que dicha composición comprende un
antiadherente.
22. Composición según la reivindicación 21, en
la que el antiadherente es dióxido de silicio.
23. Composición según la reivindicación 22, en
la que el dióxido de silicio es syloid 244 y comprende entre
aproximadamente 0,4% p/p y aproximadamente el 0,5% p/p de la
composición.
24. Composición según cualquiera de las
reivindicaciones 1 a 23, en la que dicha composición comprende un
lubricante.
25. Composición según la reivindicación 24, en
la que dicho lubricante es estearato de magnesio.
26. Composición según la reivindicación 25, en
la que el estearato de magnesio comprende entre aproximadamente el
0,2% y aproximadamente el 2,0% p/p de la composición.
27. Composición según cualquiera de las
reivindicaciones 1 a 26, en la que además dicha composición
comprende por lo menos un agente farmacéutico activo adicional.
28. Composición según la reivindicación 27, en
la que el agente farmacéutico activo adicional es un agente
diurético.
29. Composición según la reivindicación 27 ó
28, en la que el agente activo adicional es hidroclorotiazida.
30. Composición según la reivindicación 1, en
la que la composición comprende, en peso, 75% de irbesartán, y en
peso, aproximadamente 10% de aglutinante, aproximadamente 7,5% de
diluyente, aproximadamente 4% de disgregador, aproximadamente 2% de
tensioactivo, aproximadamente 1% de lubricante y aproximadamente
0,5% de antiadherente; en la que dicho aglutinante consiste en
almidón pregelatinizado y povidona; dicho diluyente es microcelulosa
cristalina y dicho disgregador es croscarmelosa sódica, dicho
tensioactivo es poloxámero 188, dicho lubricante es estearato de
magnesio y dicho antiadherente es dióxido de silicio.
31. Composición según la reivindicación 1, en
la que la composición comprende, en peso, 79,79% de irbesartán, y
los excipientes farmacéuticos comprenden en peso, aproximadamente
8,5% de aglutinante, aproximadamente 5,9% de diluyente,
aproximadamente 3,1% de disgregador, aproximadamente 1% de
tensioactivo, aproximadamente 1% de lubricante y aproximadamente
0,5% de antiadherente; en la que dicho aglutinante consiste en
almidón pregelatinizado y povidona; dicho diluyente es
microcelulosa cristalina, dicho disgregador es croscarmelosa sódica,
dicho tensioactivo es poloxámero 188, dicho lubricante es estearato
de magnesio y dicho antiadherente es dióxido de silicio.
32. Composición según la reivindicación 30 ó
31, en la que dicha composición es un comprimido, de modo que el
comprimido tiene un rendimiento de disolución de modo que más del
85% del irbesartán contenido en la misma se disuelve en 30 minutos
en las condiciones siguientes: aparato 2 de USP, colocando el
comprimido en 1000 ml de ácido clorhídrico 0,1 N a 37ºC con una
velocidad del agitador de
50 rpm.
50 rpm.
33. Composición según la reivindicación 5, en
la que el comprimido se prepara mediante un procedimiento de
granulación en húmedo.
34. Composición según la reivindicación 1, que
presenta un perfil de disolución según el cual más del 80% del
irbesartán se disuelve en 10 minutos utilizando el aparato 2 de USP,
colocando el comprimido en 1000 ml de ácido clorhídrico 0,1 N a
37ºC con una velocidad del agitador de 50 rpm.
35. Composición según la reivindicación 1, que
presenta un perfil de disolución según el cual más del 85% del
irbesartán se disuelve en aproximadamente 10 minutos utilizando el
aparato 2 de USP, colocando el comprimido en 1000 ml de ácido
clorhídrico 0,1 N a 37ºC con una velocidad del agitador de 50
rpm.
36. Composición según la reivindicación 1, que
presenta un perfil de disolución según el cual por lo menos
aproximadamente el 75% del irbesartán se disuelve en aproximadamente
5 minutos, por lo menos aproximadamente el 85% del irbesartán se
disuelve en aproximadamente 10 minutos y por lo menos
aproximadamente el 95% del irbesartán se disuelve en
aproximadamente 20 minutos utilizando el aparato 2 de USP, colocando
el comprimido en 1000 ml de ácido clorhídrico 0,1 N a 37ºC con una
velocidad del agitador de 50 rpm.
37. Composición según la reivindicación 1, en
la que la composición comprende, en peso, 79,79% de irbesartán,
entre aproximadamente el 3% y aproximadamente el 7% de
hidroclorotiazida, entre aproximadamente 5,3% y aproximadamente
7,5% de aglutinante, entre aproximadamente 3,5% y aproximadamente 6%
de diluyente, entre aproximadamente 3% y aproximadamente 3,2% de
disgregador, entre aproximadamente 1% y aproximadamente 1,1% de
lubricante, y entre aproximadamente 0,4% y aproximadamente 0,5% de
antiadherente; en la que dicho aglutinante consiste en almidón
pregelatinizado y povidona; dicho diluyente es microcelulosa
cristalina, dicho disgregador es croscarmelosa sódica, dicho
lubricante es estearato de magnesio y dicho antiadherente es dióxido
de silicio.
38. Composición según la reivindicación 36, en
la que la composición comprende, en peso, 79,79% de irbesartán,
2,13% de povidona, 6,38% de almidón pregelatinizado, 3,15% de
croscarmelosa sódica, 1,01% de poloxámero 188, 5,96% de celulosa
microcristalina, 1,01% de estearato de magnesio y 0,43% de dióxido
de silicio.
39. Composición según la reivindicación 37, en
la que la composición comprende 150 mg de irbesartán y 12,5 mg de
hidroclorotiazida.
40. Composición según la reivindicación 37 en
la que la composición comprende, en peso, 79% de irbesartán,
aproximadamente 3,3% de hidroclorotiazida, aproximadamente 3,1% de
almidón pregelatinizado, aproximadamente 2,1% de povidona,
aproximadamente 5,3% de celulosa microcristalina, aproximadamente
4,7% de croscarmelosa sódica, aproximadamente 0,4% de dióxido de
silicio y aproximadamente 1% de estearato de magnesio.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57742704P | 2004-06-04 | 2004-06-04 | |
US577427P | 2004-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2282062T1 true ES2282062T1 (es) | 2007-10-16 |
Family
ID=35463389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES05775601T Pending ES2282062T1 (es) | 2004-06-04 | 2005-06-02 | Composicion farmaceutica que contiene irbesartan. |
Country Status (11)
Country | Link |
---|---|
US (2) | US8226977B2 (es) |
EP (1) | EP1750862B1 (es) |
JP (2) | JP4880591B2 (es) |
AT (1) | ATE493973T1 (es) |
AU (1) | AU2005249794A1 (es) |
CA (1) | CA2568640C (es) |
DE (1) | DE602005025755D1 (es) |
ES (1) | ES2282062T1 (es) |
IL (1) | IL179718A0 (es) |
PL (1) | PL1750862T3 (es) |
WO (1) | WO2005118166A2 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602006013261D1 (de) * | 2006-01-09 | 2010-05-12 | Krka D D | Irbesartan enthaltende feste Zubereitung |
DE102006006588A1 (de) * | 2006-02-13 | 2007-08-16 | Ratiopharm Gmbh | Schnell freisetzende Irbesartan-haltige pharmazeutische Zusammensetzung |
GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
GB0617171D0 (en) * | 2006-08-31 | 2006-10-11 | Generics Uk Ltd | Novel compositions and methods |
CA2563690C (en) * | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
JP5527921B2 (ja) * | 2006-12-22 | 2014-06-25 | エスエス製薬株式会社 | 苦味を隠蔽した経口固形組成物 |
WO2008102235A1 (en) * | 2007-02-20 | 2008-08-28 | Aurobindo Pharma Limited | Controlled release formulations of alfuzosin |
US20090048317A1 (en) * | 2007-08-01 | 2009-02-19 | Michael Fox | Formulations of candesartan |
DE602007007968D1 (de) | 2007-11-28 | 2010-09-02 | Lesvi Laboratorios Sl | Pharmazeutische Formulierungen mit Irbesartan |
JP5296456B2 (ja) * | 2008-08-26 | 2013-09-25 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
WO2011010316A1 (en) * | 2009-07-20 | 2011-01-27 | Hetero Research Foundation | Pharmaceutical compositions of irbesartan |
WO2011141783A2 (en) | 2010-04-13 | 2011-11-17 | Micro Labs Limited | Pharmaceutical composition comprising irbesartan |
JP5946135B2 (ja) * | 2012-03-29 | 2016-07-05 | 塩野義製薬株式会社 | トリクロルメチアジドおよび結晶セルロースを含有する固形製剤 |
JP6018420B2 (ja) * | 2012-06-05 | 2016-11-02 | ニプロ株式会社 | アンジオテンシンii受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物 |
KR20140030505A (ko) * | 2012-08-31 | 2014-03-12 | 한미약품 주식회사 | 이베살탄 및 HMG-CoA 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 |
JP5714652B2 (ja) * | 2013-06-13 | 2015-05-07 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
JP5978335B2 (ja) * | 2015-03-11 | 2016-08-24 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
JP6445923B2 (ja) * | 2015-04-22 | 2018-12-26 | ダイト株式会社 | イルベサルタン含有錠剤の調製方法 |
JP6737060B2 (ja) * | 2015-09-11 | 2020-08-05 | ニプロ株式会社 | イルベサルタンを含有する医薬組成物の製造方法 |
JP6151413B2 (ja) * | 2016-07-25 | 2017-06-21 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
CN116730921A (zh) | 2017-02-17 | 2023-09-12 | 文涵治疗有限公司 | Ag-10的制备方法、其中间体及其盐 |
JP2017141299A (ja) * | 2017-05-24 | 2017-08-17 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
JP2018168185A (ja) * | 2018-07-05 | 2018-11-01 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
BR112020026493A2 (pt) * | 2018-08-17 | 2021-03-23 | Eidos Therapeutics, Inc. | Formulações de ag10 |
JP2019203031A (ja) * | 2019-09-06 | 2019-11-28 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
Family Cites Families (371)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4327080A (en) | 1981-07-13 | 1982-04-27 | E. R. Squibb & Sons, Inc. | Novel Bendroflumethiazide formulations and method |
US5002776A (en) * | 1983-12-22 | 1991-03-26 | Elan Corporation, Plc | Controlled absorption diltiazem formulations |
GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
US4808413A (en) * | 1987-04-28 | 1989-02-28 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions in the form of beadlets and method |
US5049394A (en) | 1987-09-11 | 1991-09-17 | E. R. Squibb & Sons, Inc. | Pharmaceutical composition containing high drug load and method for preparing same |
US5744166A (en) | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
US5212165A (en) | 1989-10-23 | 1993-05-18 | E. R. Squibb & Sons, Inc. | Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5270317A (en) | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
FR2659967B1 (fr) | 1990-03-20 | 1992-07-24 | Sanofi Sa | Derives d'imidazolinone n-substitues, leur preparation, les compositions pharmaceutiques en contenant. |
FR2681067B1 (fr) | 1991-09-10 | 1993-12-17 | Elf Sanofi | Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant. |
IE910913A1 (en) | 1990-03-20 | 1991-09-25 | Sanofi Sa | N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them |
FR2665702B1 (fr) | 1990-08-08 | 1994-02-25 | Sanofi | Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant. |
US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
US5140012A (en) | 1990-05-31 | 1992-08-18 | E. R. Squibb & Sons, Inc. | Method for preventing onset of restenosis after angioplasty employing pravastatin |
US5622985A (en) | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
US5137902A (en) | 1990-07-13 | 1992-08-11 | E. I. Du Pont De Nemours And Company | 4-alkylimidazole derivatives and anti-hypertensive use thereof |
US5089626A (en) * | 1990-08-23 | 1992-02-18 | Merck & Co., Inc. | Process for preparing an angiotensin II antagonist |
US5032578A (en) | 1990-09-17 | 1991-07-16 | E. R. Squibb & Sons, Inc. | Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors |
US5098889A (en) * | 1990-09-17 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors |
US20010016594A1 (en) | 1990-12-14 | 2001-08-23 | Smithkline Beecham P.L.C. | Medicament |
US6025380A (en) * | 1990-12-14 | 2000-02-15 | Smithkline Beecham Plc | Medicament |
US6028091A (en) * | 1990-12-14 | 2000-02-22 | Smithkline Beecham Plc | Medicament |
DK0565634T3 (da) | 1990-12-14 | 1999-09-27 | Smithkline Beecham Corp | Angiotensin-II-receptorblokkersammensætninger |
US6034114A (en) * | 1990-12-14 | 2000-03-07 | Smithkline Beecham Plc | Medicament |
US5472967A (en) | 1991-02-20 | 1995-12-05 | Synthelabo | 4-pyrimidinone derivatives their preparation and their application in therapy |
FR2673427B1 (fr) | 1991-03-01 | 1993-06-18 | Sanofi Elf | Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. |
FR2677984B1 (fr) | 1991-06-21 | 1994-02-25 | Elf Sanofi | Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant. |
DE59202126D1 (de) * | 1991-07-01 | 1995-06-14 | Gergely Gerhard | Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung. |
CZ36294A3 (en) | 1991-08-19 | 1994-07-13 | Du Pont | Substituted imidazilonone derivatives and pharmaceutical preparations based thereon |
CA2115990A1 (en) | 1991-08-19 | 1993-03-04 | George Albert Boswell | Angiotensin ii receptor blocking imidazolinone derivatives |
EP0553777B1 (en) * | 1992-01-29 | 2002-04-24 | Takeda Chemical Industries, Ltd. | Fast dissolving tablet and its production |
FR2688781B1 (fr) | 1992-03-23 | 1994-07-01 | Sanofi Elf | Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. |
GB9208116D0 (en) | 1992-04-13 | 1992-05-27 | Ici Plc | Therapeutic agents |
US6673824B1 (en) * | 1992-05-06 | 2004-01-06 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
EP0577023A3 (en) | 1992-07-01 | 1996-12-18 | Hoechst Ag | Angiotensin-ii receptor-antagonists for the treatment of arrhythmices |
US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
WO1994009778A1 (en) | 1992-10-26 | 1994-05-11 | Merck & Co., Inc. | Combinations of angiotensin-ii receptor antagonists and diuretics |
US5457112A (en) | 1992-12-14 | 1995-10-10 | Synthelabo | 3-(6-quinolylmethyl)-4H-imidazol-4-one derivatives, their preparation and their application in therapy |
PT693924E (pt) * | 1993-02-22 | 2004-09-30 | American Biosciences | Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos |
US5914132A (en) | 1993-02-26 | 1999-06-22 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
EP0635263A3 (en) | 1993-06-28 | 1995-09-27 | American Cyanamid Co | Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue. |
FR2708608B1 (fr) | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant. |
FR2708606B1 (fr) | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5824696A (en) | 1993-09-01 | 1998-10-20 | Smithkline Beecham Corporation | Medicaments |
US6174917B1 (en) * | 1993-09-08 | 2001-01-16 | Pharmacy And Therapeutic Advisory Consultancy Ltd. | Method of treating liver disease and like indications with vasodilating agents |
US5464854A (en) | 1993-11-11 | 1995-11-07 | Depadova; Anathony S. | Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S. |
WO1995014037A1 (en) * | 1993-11-17 | 1995-05-26 | Ibah, Inc. | Transparent liquid for encapsulated drug delivery |
US5536505A (en) | 1993-12-15 | 1996-07-16 | Eastman Chemical Company | Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends |
US5523095A (en) | 1993-12-15 | 1996-06-04 | Eastman Chemical Company | Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends |
CA2181461A1 (en) * | 1994-02-08 | 1995-08-17 | Alica Huxley | Treatment of normotensive glaucoma with angiotensin ii antagonists |
JP3414539B2 (ja) * | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
US6645463B1 (en) | 1994-05-16 | 2003-11-11 | The Board Of Regents Of The University Of Michigan | Blood-pool selective carrier for lipophilic imaging agents |
US5464633A (en) | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
US5541209A (en) | 1994-08-22 | 1996-07-30 | Bristol-Myers Squibb Company | Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative |
US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
FR2725987B1 (fr) | 1994-10-19 | 1997-01-10 | Sanofi Sa | Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive |
US6485726B1 (en) * | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US5780473A (en) | 1995-02-06 | 1998-07-14 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
CA2168066A1 (en) | 1995-02-08 | 1996-08-09 | James R. Powell | Treatment of hypertension and congestive heart failure |
FR2732223B1 (fr) * | 1995-03-30 | 1997-06-13 | Sanofi Sa | Composition pharmaceutique pour administration transdermique |
US5731339A (en) * | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
US20020094346A1 (en) | 1995-05-17 | 2002-07-18 | M. D. Henry C. Lin | Method and compositions for improving digestion and absorption in the small intestine |
US5686106A (en) | 1995-05-17 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
SE9501881D0 (sv) | 1995-05-19 | 1995-05-19 | Astra Ab | New pharmacological use of AII-receptor antagonists |
CZ297975B6 (cs) | 1995-06-07 | 2007-05-09 | G. D. Searle & Co. | Farmaceutická kombinace antagonisty receptoru proangiotensin II a epoxymexrenonu pro lécení kardiovaskulárních poruch |
TW442301B (en) | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
US5994348A (en) * | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
US5645839A (en) | 1995-06-07 | 1997-07-08 | Trustees Of Boston University | Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis |
FR2735365B1 (fr) | 1995-06-14 | 1997-09-05 | Sanofi Sa | Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires |
SE9502219D0 (sv) | 1995-06-19 | 1995-06-19 | Astra Ab | Novel medical use |
US6057139A (en) * | 1995-06-29 | 2000-05-02 | Mcneil-Ppc, Inc. | Preblend of microcrystalline cellulose and lactase for making tablets |
US5846990A (en) | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
FR2740136B1 (fr) | 1995-10-24 | 1998-01-09 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant |
FR2740686B1 (fr) | 1995-11-03 | 1998-01-16 | Sanofi Sa | Formulation pharmaceutique lyophilisee stable |
ES2189940T3 (es) * | 1996-02-29 | 2003-07-16 | Novartis Ag | Antagonista de receptor at1 para la estimulacion de la apoptosis. |
FR2746013B1 (fr) | 1996-03-18 | 1998-05-29 | Sanofi Sa | Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus |
US5939446A (en) | 1996-04-09 | 1999-08-17 | Bristol-Myers Squibb Co. | Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists |
DE69734405T2 (de) * | 1996-07-15 | 2006-08-03 | Sankyo Co., Ltd. | Verwendung von CS-866 (Olmersartan) zur Herstellung eines Medikaments für die Behandlung von Arteriosklerose |
US5891469A (en) | 1997-04-02 | 1999-04-06 | Pharmos Corporation | Solid Coprecipitates for enhanced bioavailability of lipophilic substances |
HRP970493A2 (en) * | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
ES2257771T3 (es) | 1996-10-28 | 2006-08-01 | Amersham Health As | Agentes de contraste. |
US6008221A (en) | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
US6019988A (en) * | 1996-11-18 | 2000-02-01 | Bristol-Myers Squibb Company | Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage |
FR2757157B1 (fr) | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
US6201002B1 (en) * | 1997-01-10 | 2001-03-13 | Merck & Co., Inc. | Method for reducing mortality with an angiotensin II antagonist |
EP0855392A3 (de) * | 1997-01-22 | 2000-01-05 | Hoechst Aktiengesellschaft | Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
US5788987A (en) | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
WO1998033781A1 (en) | 1997-01-30 | 1998-08-06 | Bristol-Myers Squibb Company | Method for preventing or treating low renin hypertension by administering an endothelin antagonist |
TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
US5846985A (en) | 1997-03-05 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
TW580397B (en) | 1997-05-27 | 2004-03-21 | Takeda Chemical Industries Ltd | Solid preparation |
DE19724696A1 (de) | 1997-06-12 | 1998-12-24 | Hexal Ag | Pharmazeutische Zubereitung mit drei Pelletarten |
EP0986373B1 (en) * | 1997-06-13 | 2004-03-17 | Nanopharm AG | Drug targeting system, method of its preparation and its use |
IT1292437B1 (it) | 1997-06-30 | 1999-02-08 | Zambon Spa | Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti |
HU218679B (hu) | 1997-07-25 | 2000-10-28 | Sanofi-Synthelabo | Eljárás imidazolonok előállítására és intermedierjeik |
US20010044584A1 (en) | 1997-08-28 | 2001-11-22 | Kensey Kenneth R. | In vivo delivery methods and compositions |
GT199800126A (es) | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
NL1006903C2 (nl) * | 1997-09-01 | 1999-03-04 | Johannes Gerardus Van Gemert | Werkwijze voor het verdichten van vormzand. |
KR100551221B1 (ko) | 1997-09-09 | 2006-02-10 | 리오트로픽테라피우틱스 인코퍼레이션 | 코팅된 입자, 그 제조방법 및 그 사용방법 |
US6248358B1 (en) | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
US20030077229A1 (en) | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
HUP0003982A3 (en) | 1997-10-17 | 2002-01-28 | Eurogene Ltd | The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function |
DE19750529A1 (de) * | 1997-11-14 | 1999-05-20 | Basf Ag | Neue heterocyclisch substituierte alpha-Hydroxycarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten |
JPH11137208A (ja) * | 1997-11-14 | 1999-05-25 | Nikken Chem Co Ltd | 口腔内速溶性固形物及びその製造方法 |
PL197989B1 (pl) * | 1997-12-19 | 2008-05-30 | Smithkline Beecham Corp | Sposób wytwarzania szybko rozpraszających się tabletek do podawania doustnego, szybko rozpraszający się preparat farmaceutyczny w postaci tabletek i szybko rozpraszająca się, farmaceutycznie dopuszczalna, tabletka do podawania doustnego |
US6162922A (en) | 1998-01-30 | 2000-12-19 | Bristol-Myers Squibb Co. | Method for preparing N-substituted heterocyclic derivatives using a phase-transfer catalyst |
HRP980532B1 (en) * | 1998-10-02 | 2005-06-30 | Pliva | Novel crystalline torasemide modification |
AU747110B2 (en) | 1998-02-25 | 2002-05-09 | Merck & Co., Inc. | Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist |
ZA991706B (en) | 1998-03-04 | 2000-10-03 | Takeda Chemical Industries Ltd | Sustained-release preparation for Aii Antagonist, production and use thereof. |
FR2775598A1 (fr) | 1998-03-06 | 1999-09-10 | Sanofi Sa | Compositions pharmaceutiques contenant en association un antagoniste selectif des recepteurs v1a de l'arginine-vasopressine et un antagoniste selectif des recepteur v2 de l'arginine-vasopressine |
US6284363B1 (en) | 1998-03-23 | 2001-09-04 | Fuji Polymer Industries Co., Ltd. | Electromagnetic wave absorbing thermoconductive silicone gel molded sheet and method for producing the same |
US20040062802A1 (en) | 1998-04-02 | 2004-04-01 | Hermelin Victor M. | Maximizing effectiveness of substances used to improve health and well being |
FR2778103A1 (fr) | 1998-04-29 | 1999-11-05 | Sanofi Sa | Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii |
KR100388120B1 (ko) | 1998-05-11 | 2003-06-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 저혈당 및 저지질혈 활성을 갖는 옥시이미노알칸산 유도체 |
WO1999065500A1 (en) | 1998-06-17 | 1999-12-23 | Bristol-Myers Squibb Company | Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination |
IT1301759B1 (it) | 1998-06-19 | 2000-07-07 | Nicox Sa | Sali nitrati di farmaci antiipertensivi |
FR2780403B3 (fr) * | 1998-06-24 | 2000-07-21 | Sanofi Sa | Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant |
US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
FR2780890B3 (fr) | 1998-07-10 | 2000-09-01 | Sanofi Sa | Utilisation d'une composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et l'indomethacine pour le traitement des glomerulonephrites chroniques |
JP3404648B2 (ja) | 1998-07-28 | 2003-05-12 | 武田薬品工業株式会社 | 速崩壊性固形製剤 |
US6284763B1 (en) | 1998-08-26 | 2001-09-04 | Queen's University At Kingston | Methods for remodeling neuronal and cardiovascular pathways |
US6489307B1 (en) | 1998-09-14 | 2002-12-03 | University Of Florida | Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use |
FR2783422A1 (fr) | 1998-09-21 | 2000-03-24 | Sanofi Sa | Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire |
US6531152B1 (en) * | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
US7815937B2 (en) | 1998-10-27 | 2010-10-19 | Biovail Laboratories International Srl | Quick dissolve compositions and tablets based thereon |
US6596747B2 (en) | 1998-10-29 | 2003-07-22 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
US20040141925A1 (en) | 1998-11-12 | 2004-07-22 | Elan Pharma International Ltd. | Novel triamcinolone compositions |
WO2000029049A1 (en) * | 1998-11-13 | 2000-05-25 | Elan Pharma International Limited | Drug delivery systems and methods |
TNSN99224A1 (fr) | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
FR2787330A1 (fr) | 1998-12-18 | 2000-06-23 | Sanofi Sa | Composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et un immunosuppresseur pour la prevention ou le traitement des complications vasculaires du rejet de greffe |
KR100349597B1 (ko) | 1999-01-12 | 2002-08-22 | 삼성전자 주식회사 | 광도파로 소자 및 그 제조방법 |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US20030104048A1 (en) | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
EP1169322B8 (en) | 1999-03-08 | 2006-09-13 | Medicure Inc. | Pyridoxal analogues for the treatment of disorders caused by a deficiency in vitamin b6 |
JP3695978B2 (ja) | 1999-03-16 | 2005-09-14 | 三洋電機株式会社 | 渦巻状電極体を備えたアルカリ蓄電池 |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6632451B2 (en) | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
US6387894B1 (en) | 1999-06-11 | 2002-05-14 | Pfizer Inc. | Use of CRF antagonists and renin-angiotensin system inhibitors |
BR0011928A (pt) | 1999-06-25 | 2002-04-09 | Inst For Pharm Discovery Inc | Composto, composição farmacêutica, uso de, um composto e métodos para o tratamento de complicações diabéticas, para o tratamento ou a prevenção do desenvolvimento de condições de doença associadas com velocidade de condução neuronial prejudicada e de neuropatia diabética |
US20030235595A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
SE9902597D0 (sv) | 1999-07-06 | 1999-07-06 | Astra Ab | New use |
CA2383252A1 (en) * | 1999-08-24 | 2001-03-01 | Medicure International Inc. | Treatment of cardiovascular related pathologies |
US6432989B1 (en) | 1999-08-27 | 2002-08-13 | Pfizer Inc | Use of CRF antagonists to treat circadian rhythm disorders |
US6555551B1 (en) | 1999-08-31 | 2003-04-29 | Mutual Pharmaceutical Co., Inc. | Stable formulations of ACE inhibitors, and methods for preparation thereof |
US20030225124A1 (en) | 1999-08-31 | 2003-12-04 | Spiridon Spireas | Stable formulations of ACE inhibitors, and methods for preparation thereof |
EP1212053A4 (en) * | 1999-09-08 | 2004-08-11 | Nitromed Inc | METHODS FOR THE TREATMENT AND PROPHYLAXIS OF CONGESTIVE HEART FAILURE BY HYDRALAZIN COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
AU8026200A (en) | 1999-10-19 | 2001-04-30 | Board Of Regents, The University Of Texas System | Treatment of heart disease with cox-2 inhibitors |
EP1093814A1 (en) | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US7537785B2 (en) | 1999-10-29 | 2009-05-26 | Nitromed, Inc. | Composition for treating vascular diseases characterized by nitric oxide insufficiency |
AU780261B2 (en) | 1999-10-29 | 2005-03-10 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
US7235237B2 (en) | 1999-10-29 | 2007-06-26 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
US20030113330A1 (en) | 1999-11-08 | 2003-06-19 | Uhal Bruce D. | Methods for treating pulmonary fibrosis |
US20030180352A1 (en) | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
IL133196A0 (en) * | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
MY125533A (en) * | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
EP1106210A3 (en) | 1999-12-07 | 2003-12-03 | Pfizer Products Inc. | Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications |
FR2803525B1 (fr) * | 2000-01-06 | 2002-05-03 | Sod Conseils Rech Applic | Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle |
EP1253925A1 (en) | 2000-01-28 | 2002-11-06 | Bristol-Myers Squibb Company | Tetrahydropyrimidone inhibitors of fatty acid binding protein and method |
US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
CA2400124C (en) * | 2000-02-18 | 2010-12-14 | Kazuaki Ikeya | Tnf-.alpha. inhibitors |
EP1258254A4 (en) | 2000-02-21 | 2004-02-04 | Takeda Chemical Industries Ltd | COMPOSITIONS FOR DELAYED DELIVERY OF PHYSIOLOGICALLY ACTIVE COMPOUNDS THAT ARE LOW WATER-SOLUBLE, METHOD FOR THE PRODUCTION AND USE THEREOF |
US20030152636A1 (en) | 2000-02-23 | 2003-08-14 | Nanopharm Ag | Method of treating cancer |
PT1268498E (pt) | 2000-02-29 | 2005-07-29 | Medicure Int Inc | Fosfonatos cardioprotectores |
AU2001238718A1 (en) * | 2000-03-02 | 2001-09-12 | The Institutes For Pharmaceutical Discovery, Llc | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
WO2001068136A1 (fr) | 2000-03-17 | 2001-09-20 | Ajinomoto Co., Inc. | Medicaments permettant de traiter les complications du diabete et des neuropathies et utilisation de ces medicaments |
DE10014588A1 (de) | 2000-03-27 | 2001-10-04 | Basf Ag | Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung |
US6436684B1 (en) | 2000-03-27 | 2002-08-20 | Applera Corporation | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
AU2001242184A1 (en) * | 2000-03-28 | 2001-10-08 | Queen:S University At Kingston | Methods for effecting neuroprotection using a potassium channel modulator |
EP1277730A4 (en) | 2000-03-28 | 2005-03-16 | HEMMER OF NEOVASCULARIZATION | |
DE10015479A1 (de) | 2000-03-29 | 2001-10-11 | Basf Ag | Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität |
JP2003533440A (ja) * | 2000-04-03 | 2003-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | 隔離心収縮期高血圧症を処置するバソペプチダーゼ抑制剤 |
GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
GB2361185A (en) | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
US6881860B2 (en) * | 2000-04-11 | 2005-04-19 | Atherogenics, Inc. | Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality |
SK14642002A3 (sk) * | 2000-04-12 | 2003-05-02 | Novartis Ag | Kombinované farmaceutické prostriedky obsahujúce antagonistu AT1-receptora a/alebo inhibítor HMG-CoA reduktázy a/alebo ACE inhibítor |
US20030083342A1 (en) | 2002-08-27 | 2003-05-01 | Steele Ronald Edward | Combination of organic compounds |
WO2003030868A1 (en) | 2001-10-09 | 2003-04-17 | Bristol-Myers Squibb Company | Flashmelt oral dosage formulation |
CA2311734C (en) | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
AR030557A1 (es) | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
CA2408245C (en) * | 2000-05-10 | 2009-04-28 | Rtp Pharma Inc. | Media milling |
AU2001259592B2 (en) * | 2000-05-11 | 2005-02-24 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
AU2001264729A1 (en) * | 2000-05-22 | 2001-12-03 | Nitromed, Inc. | Thromboxane inhibitors, compositions and methods of use related applications |
AU2001258784A1 (en) | 2000-05-22 | 2001-12-03 | Takeda Chemical Industries Ltd. | Tyrosine phosphatase inhibitors |
US20020049155A1 (en) | 2000-05-31 | 2002-04-25 | Hogenkamp Henricus P.C. | Cobalamin compounds useful as cardiovascular agents and as imaging agents |
US20030212124A1 (en) | 2001-05-30 | 2003-11-13 | Kevorkian Robert C. | Use of ace inhibitors for treatment of patients suffering from behavioral disorders |
US7678387B2 (en) | 2000-06-06 | 2010-03-16 | Capricorn Pharma, Inc. | Drug delivery systems |
US20020044962A1 (en) | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
US6544981B2 (en) * | 2000-06-09 | 2003-04-08 | Bristol-Myers Squibb Company | Lactam inhibitors of factor Xa and method |
US20020013334A1 (en) * | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
US6620821B2 (en) | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
US6627636B2 (en) | 2000-06-15 | 2003-09-30 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
US6670355B2 (en) | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
US20020013335A1 (en) * | 2000-06-16 | 2002-01-31 | American Home Products Corporation | Method of treating cardiovascular disease |
DE10029201A1 (de) * | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
AU2001270070B2 (en) * | 2000-06-22 | 2006-03-16 | Nitromed, Inc. | Nitrosated and nitrosylated taxanes, compositions and methods of use |
NZ523613A (en) | 2000-06-27 | 2005-02-25 | Anges Mg Inc | Pharmaceutical compositions for angiogenic therapy |
ATE422357T1 (de) * | 2000-06-28 | 2009-02-15 | Merck & Co Inc | Verwendung von allopurinol zur behandlung von bluthochdruck |
US20030114420A1 (en) | 2000-06-28 | 2003-06-19 | Salvati Mark E. | Fused cyclic modulators of nuclear hormone receptor function |
WO2002002081A1 (en) | 2000-07-05 | 2002-01-10 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and methods of using same |
US6375982B1 (en) * | 2000-07-05 | 2002-04-23 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and method of using same |
WO2002004421A2 (en) | 2000-07-07 | 2002-01-17 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
US20030176426A1 (en) | 2000-07-13 | 2003-09-18 | Alteon, Inc. | Method for treating fibrotic diseases or other indications with imidazolium agents |
PL360398A1 (en) | 2000-07-13 | 2004-09-06 | Takeda Chemical Industries, Ltd. | Lipid-rich plaque inhibitors |
AU2001280546B2 (en) | 2000-07-13 | 2005-10-20 | Alteon, Inc. | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
WO2002009683A2 (en) | 2000-07-27 | 2002-02-07 | Pharmacia Corporation | Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
US6511973B2 (en) | 2000-08-02 | 2003-01-28 | Bristol-Myers Squibb Co. | Lactam inhibitors of FXa and method |
GB0020691D0 (en) | 2000-08-22 | 2000-10-11 | Boehringer Ingelheim Pharma | Pharmaceutical combination |
US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
US7166578B2 (en) | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US20030187038A1 (en) | 2000-08-25 | 2003-10-02 | Yoshimi Imura | Fibrinogen-lowering agents |
US6521747B2 (en) | 2000-08-28 | 2003-02-18 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the AGTR1 gene |
CA2420844A1 (en) | 2000-08-30 | 2003-02-28 | Sankyo Company, Limited | Medicinal compositions for preventing or treating heart failure |
DE60137943D1 (de) | 2000-08-31 | 2009-04-23 | Jagotec Ag | Gemahlene partikel |
US6576644B2 (en) | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
US6595926B1 (en) | 2000-09-07 | 2003-07-22 | John H. Laragh | Method for evaluating and treating hypertension |
US6632180B1 (en) | 2000-09-07 | 2003-10-14 | John H. Laragh | Method for evaluating and treating hypertension |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
US20020048599A1 (en) | 2000-10-20 | 2002-04-25 | Thomas H. Mueller | Method for increasing tissue perfusion by co-administration of an agent that increases cGMP synthesis and an agent that inhibits cGMP degradation |
US6841671B2 (en) | 2000-10-26 | 2005-01-11 | Pfizer Inc. | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
EA200300409A1 (ru) | 2000-10-26 | 2003-08-28 | Пфайзер Продактс Инк. | Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназы |
EP1334732B1 (en) * | 2000-11-17 | 2010-06-02 | Takeda Pharmaceutical Company Limited | Pharmaceutical preparation of n-[2-(1,6,7,8-tetrahydro-2h-indeno[5,4 b]furan-8-yl)ethyl]propionamide coated with a copolyvidone-containing coating free of polyethylene glycol |
JP2004536023A (ja) | 2000-11-20 | 2004-12-02 | ブリストル−マイヤーズ スクイブ カンパニー | aP2インヒビターとしてのピリドン誘導体 |
JP4107831B2 (ja) | 2000-11-21 | 2008-06-25 | 第一三共株式会社 | 医薬組成物 |
AU1788502A (en) | 2000-11-28 | 2002-06-11 | Univ Chicago | Genetically engineered herpes virus for the treatment of cardiovascular disease |
JP2004514703A (ja) | 2000-12-01 | 2004-05-20 | ノバルティス アクチエンゲゼルシャフト | 有機化合物の組合せ剤 |
EP1346722B1 (en) * | 2000-12-01 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive substance |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
WO2002049630A2 (en) | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Method for preventing or treating pain by administering an endothelin antagonist |
CN1238363C (zh) | 2000-12-28 | 2006-01-25 | 橘生药品工业株式会社 | 吡喃葡糖氧基吡唑衍生物及其在药物中的应用 |
WO2002053101A2 (en) | 2000-12-29 | 2002-07-11 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
JP2004525904A (ja) | 2000-12-29 | 2004-08-26 | アルテオン インコーポレイテッド | 線維性疾患又は他の適応症iiicの治療方法 |
WO2002053161A1 (en) | 2000-12-29 | 2002-07-11 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
ITMI20010129A1 (it) | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
CA2434488A1 (en) | 2001-01-26 | 2002-08-01 | Harry R. Davis | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
JP2004517919A (ja) | 2001-01-26 | 2004-06-17 | シェーリング コーポレイション | 血管状態の処置のための心臓血管薬剤とステロール吸収インヒビターとの組み合わせ |
TW200744638A (en) * | 2001-01-26 | 2007-12-16 | Schering Corp | Combinations of bile acid sequestrant(s) and sterol absorption inhibitors and treatments for vascular indications |
AR032403A1 (es) | 2001-01-26 | 2003-11-05 | Schering Corp | Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares |
HUP0303915A3 (en) | 2001-01-26 | 2012-12-28 | Merck Sharp & Dohme | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
EP1358178A2 (en) | 2001-01-30 | 2003-11-05 | Bristol-Myers Squibb Company | Sulfonamide lactam inhibitors of factor xa |
TWI255817B (en) | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
FI114483B (fi) * | 2001-02-20 | 2004-10-29 | Jurilab Ltd Oy | Menetelmä kohonneen verenpaineen riskin osoittamiseksi ja sen käytöt |
TW593329B (en) | 2001-02-26 | 2004-06-21 | Kissei Pharmaceutical | Glucopyranosyloxypyrazole derivatives and pharmaceutical uses thereof |
DE60237580D1 (de) | 2001-02-27 | 2010-10-21 | Kissei Pharmaceutical | Glykopyranosyloxypyrazolderivate und deren medizinische verwendung |
ATE297902T1 (de) * | 2001-02-28 | 2005-07-15 | Pfizer Prod Inc | Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren |
US20030119010A1 (en) | 2001-03-01 | 2003-06-26 | University Of Queensland | Polynucleotides and polypeptides linked to a disease or condition |
CA2438272A1 (en) | 2001-03-02 | 2002-10-10 | John Macor | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
CA2439691A1 (en) | 2001-03-02 | 2002-09-12 | Bristol-Myers Squibb Company | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US6642244B2 (en) | 2001-03-16 | 2003-11-04 | Bristol-Myers Squibb Co. | Pyrazolopyridopyrimidine inhibitors of cGMP phosphodiesterase |
GEP20053675B (en) | 2001-03-30 | 2005-11-25 | Pfizer Prod Inc | Pyridazinone Aldose Reductase Inhibitors |
EP1247809A3 (en) * | 2001-03-30 | 2003-12-17 | Pfizer Products Inc. | Triazine compounds useful as sorbitol dehydrogenase inhibitors |
HUP0600232A2 (en) | 2001-04-11 | 2006-08-28 | Bristol Myers Squibb Co | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
US20030004199A1 (en) * | 2001-04-12 | 2003-01-02 | Isabelle Ounis | Method for preventing or treating pulmonary inflammation by administering an endothelin antagonist |
AU2002258798A1 (en) | 2001-04-13 | 2002-10-28 | Children's Hospital Medical Center | Methods for the treatment of hepatic disorders |
WO2002087503A2 (en) | 2001-04-26 | 2002-11-07 | Vanderbilt University | Compositions and methods for treating colorectal polyps and cancer |
JP2004528337A (ja) | 2001-05-02 | 2004-09-16 | ニトロメド インコーポレーテッド | ニトロソ化およびニトロシル化ネビボロール、ならびにその代謝産物、組成物、および使用方法 |
US20020168393A1 (en) | 2001-05-08 | 2002-11-14 | Ryota Sugimoto | Implantable medical material and implantable medical device |
US20030073705A1 (en) | 2001-05-14 | 2003-04-17 | Shahnaz Shahinfar | Method of treatment |
US6777443B2 (en) | 2001-05-15 | 2004-08-17 | Novartis Ag | Dipeptide derivatives |
US20030078190A1 (en) | 2001-05-25 | 2003-04-24 | Weinberg Marc S. | Methods for tissue protection using highly effective inhibition of the renin-angiotensin system |
US20030060451A1 (en) * | 2001-05-29 | 2003-03-27 | Rajneesh Taneja | Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin |
US20030092736A1 (en) | 2001-05-30 | 2003-05-15 | Cheng Peter T. | Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
CA2448294A1 (en) * | 2001-05-30 | 2002-12-05 | Alteon Inc. | Method for treating fibrotic diseases or other indications vi |
US7105556B2 (en) | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
US20030027820A1 (en) * | 2001-05-30 | 2003-02-06 | Alteon, Inc. | Method for treating fibrotic diseases or other indications V |
US6967212B2 (en) | 2001-05-30 | 2005-11-22 | Bristol-Myers Squibb Company | Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
US20040156903A1 (en) | 2002-05-22 | 2004-08-12 | Abrams Andrew L.. | Metering and packaging of controlled release medication |
ATE526973T1 (de) | 2001-06-18 | 2011-10-15 | Noven Pharma | Verbesserte arzneimittelabgabe in transdermalen systemen |
WO2003006023A1 (en) * | 2001-07-13 | 2003-01-23 | Bristol-Myers Squibb Company | Pyrazinone inhibitors of fatty acid binding protein and method |
US20030158090A1 (en) | 2001-07-23 | 2003-08-21 | Ulrik Pedersen-Bjergaard | Renin-angiotensin system in diabetes mellitus |
EP1414795A4 (en) * | 2001-07-31 | 2006-03-01 | Bristol Myers Squibb Co | BICYCLIC MODULATORS OF THE FUNCTION OF THE ANDROGEN RECEPTOR |
AU2002331707A1 (en) | 2001-08-20 | 2003-03-03 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as antithrombotic agents |
US20030124196A1 (en) | 2001-08-22 | 2003-07-03 | Susan Weinbach | Pulsatile release compositions and methods for enhanced intestinal drug absorption |
US20030083286A1 (en) | 2001-08-22 | 2003-05-01 | Ching-Leou Teng | Bioadhesive compositions and methods for enhanced intestinal drug absorption |
US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US6669955B2 (en) | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
JP4450365B2 (ja) | 2001-08-28 | 2010-04-14 | シェーリング コーポレイション | 多環式グアニンホスホジエステラーゼv阻害剤 |
WO2003020737A1 (en) | 2001-09-05 | 2003-03-13 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
US20030050620A1 (en) * | 2001-09-07 | 2003-03-13 | Isa Odidi | Combinatorial type controlled release drug delivery device |
JP2005502367A (ja) | 2001-09-11 | 2005-01-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド, ア ボディー コーポレイト | インタクトなヒト心臓における発現プロファイリング |
US6638542B2 (en) | 2001-09-20 | 2003-10-28 | Nutricia N.V. | Reducing appetite in mammals by administering procyanidin and hydroxycitric acid |
US20030119808A1 (en) | 2001-09-21 | 2003-06-26 | Schering Corporation | Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects |
US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
TWI320039B (en) | 2001-09-21 | 2010-02-01 | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | |
US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
US20030114469A1 (en) | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
EP1298223A3 (en) | 2001-09-28 | 2003-07-23 | Pfizer Products Inc. | Methods related to the A-C repeat Z-sequence upstream from the aldose reductase gene |
EP1435973A4 (en) | 2001-09-28 | 2007-05-02 | Mayo Foundation | SIMULTANEOUS ADMINISTRATION OF A TRANSPORT PROTEIN WITH CONJUGATED COBALAMINE FOR THE DISTRIBUTION OF MEDICINAL PRODUCTS |
US20030134810A1 (en) | 2001-10-09 | 2003-07-17 | Chris Springate | Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents |
US6592901B2 (en) | 2001-10-15 | 2003-07-15 | Hercules Incorporated | Highly compressible ethylcellulose for tableting |
NZ531788A (en) | 2001-10-18 | 2008-01-31 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
US20030152622A1 (en) | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
FR2831446B1 (fr) | 2001-10-26 | 2004-03-05 | Sanofi Synthelabo | Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire |
AU2916902A (en) | 2001-10-29 | 2003-05-01 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Glycogen synthase kinase function in endothelial cells |
US20030083614A1 (en) | 2001-10-30 | 2003-05-01 | Boehringer Ingelheim Pharma Kg | Controlled release endoprosthetic device |
US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
EP1442028A4 (en) * | 2001-11-06 | 2009-11-04 | Bristol Myers Squibb Co | SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS |
JP2005509038A (ja) | 2001-11-09 | 2005-04-07 | シェーリング コーポレイション | 多環式グアニン誘導体ホスホジエステラーゼv阻害剤 |
MXPA04004477A (es) | 2001-11-13 | 2004-08-11 | Schering Corp | Antagonistas del neuropeptido neuroquinina-1(nk1). |
US7361671B2 (en) | 2001-11-15 | 2008-04-22 | The Institute For Pharmaceutical Discovery, Inc. | Substituted heteroarylalkanoic acids |
EP1443919A4 (en) | 2001-11-16 | 2006-03-22 | Bristol Myers Squibb Co | DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES |
US20030206978A1 (en) | 2001-11-29 | 2003-11-06 | Bob Sherwood | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
TW200303309A (en) | 2001-12-04 | 2003-09-01 | Bristol Myers Squibb Co | Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors |
WO2003048081A2 (en) | 2001-12-04 | 2003-06-12 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
TW200302225A (en) | 2001-12-04 | 2003-08-01 | Bristol Myers Squibb Co | Substituted amino methyl factor Xa inhibitors |
US6831102B2 (en) | 2001-12-07 | 2004-12-14 | Bristol-Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
US20050176793A1 (en) | 2001-12-10 | 2005-08-11 | Reddy Reguri B. | Amorphous form of 2-n-butyl-3-((2-(1h-tetrazol-5-yl)([1,1'-biphenyl)-4-yl)methyl)-1, 3-diazaspiro(4,4')non-1-en-4-one |
PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
DE60228330D1 (de) | 2001-12-19 | 2008-09-25 | Bristol Myers Squibb Co | Kondensierte heterocyclische verbindungen und deren analoga; modulatoren der funktion von nukleären hormonrezeptoren |
EP1463510A2 (en) | 2001-12-20 | 2004-10-06 | Bristol-Myers Squibb Company | Administration of vasopeptidase inhibitors to reduce pulse pressure |
DE60222803T2 (de) | 2001-12-21 | 2008-07-17 | Supernus Pharmaceuticals, Inc. | Orale kapselformulierung mit verbesserter physikalischer stabilität |
JP2005516968A (ja) | 2001-12-29 | 2005-06-09 | ノボ ノルディスク アクティーゼルスカブ | Glp−1化合物と糖尿病後期合併症モジュレーターの組み合わせ使用 |
EA008379B1 (ru) | 2002-02-01 | 2007-04-27 | Ариад Джин Терапьютикс, Инк. | Фосфорсодержащие соединения и их применения |
AU2003209030B2 (en) | 2002-02-06 | 2009-02-05 | Stasys Technologies, Inc. | Anti-infarction molecules |
US20030221207A1 (en) | 2002-02-13 | 2003-11-27 | Pharmacia Corporation, Global Patent Department | Cardiac-specific 11beta hydroxysteroid dehydrogenase type 2 transgenic mice |
WO2003070278A1 (en) | 2002-02-19 | 2003-08-28 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors |
WO2003071870A1 (en) | 2002-02-26 | 2003-09-04 | Schlesinger Stephen L | Use of leukotriene receptor antagonist for treatment of scarring |
IL163659A0 (en) | 2002-02-27 | 2005-12-18 | Pfizer Prod Inc | Acc inhibitors |
US20040116510A1 (en) | 2002-03-05 | 2004-06-17 | Nichtberger Steven A. | Antihypertensive agent and cholesterol absorption inhibitor combination therapy |
US20030215526A1 (en) | 2002-03-08 | 2003-11-20 | Scott Stofik | Stable formulations of angiotensin converting enzyme (ACE) inhibitors |
AU2002316574B2 (en) | 2002-03-15 | 2008-05-01 | Brandeis University | Central airway administration for systemic delivery of therapeutics |
JP2005531516A (ja) | 2002-03-18 | 2005-10-20 | ファイザー・プロダクツ・インク | 選択的ep4受容体アゴニストによる治療方法 |
US20030199424A1 (en) | 2002-03-20 | 2003-10-23 | Smith Maree Therese | Method of treatment and/or prophylaxis |
JP2005530719A (ja) * | 2002-03-29 | 2005-10-13 | ニューロジェン コーポレーション | 病原性炎症要素を有する状態の治療のための組み合わせ療法 |
WO2003086282A2 (en) | 2002-04-05 | 2003-10-23 | Nitromed, Inc. | Nitric oxide donors, compositions and methods of use |
US6930085B2 (en) | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
US20040005358A1 (en) * | 2002-04-23 | 2004-01-08 | Slugg Peter H. | Modified-release vasopeptidase inhibitor formulation, combinations and method |
US20030203027A1 (en) | 2002-04-26 | 2003-10-30 | Ethicon, Inc. | Coating technique for deposition of drug substance on a substrate |
JP2005529889A (ja) | 2002-04-26 | 2005-10-06 | ファイザー・プロダクツ・インク | ピリミジン−2,4,6−トリオンメタロ−プロテイナーゼ阻害剤 |
JP2005527598A (ja) | 2002-04-26 | 2005-09-15 | ファイザー・プロダクツ・インク | トリアリール−オキシ−アリール−スピロ−ピリミジン−2,4,6−トリオンメタロプロテイナーゼ阻害剤 |
DE60302150D1 (en) * | 2002-04-26 | 2005-12-08 | Pfizer Prod Inc | N-substituiete heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trion metalloproteinase inhibitoren |
NI200300045A (es) * | 2002-04-26 | 2005-07-08 | Pfizer Prod Inc | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. |
WO2003090755A1 (en) * | 2002-04-26 | 2003-11-06 | Schering Aktiengesellschaft | Treatment of hypertension in women receiving hormone replacement therapy |
US20030203019A1 (en) | 2002-04-30 | 2003-10-30 | Cornelius John Mark | Coated conditioners for use in foods and pharmaceuticals |
TW200307667A (en) * | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
US7276514B2 (en) | 2002-05-15 | 2007-10-02 | Charitable Leadership Foundation - Medical Technology Acceleration Program | Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof |
AUPS236902A0 (en) | 2002-05-16 | 2002-06-13 | Northern Sydney Area Health Service | Composition and method for treating hypertension |
TW200407324A (en) * | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
US7375138B2 (en) | 2002-05-18 | 2008-05-20 | Sanofi-Aventis Deutschland Gmbh | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them |
US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
US7008958B2 (en) | 2002-05-21 | 2006-03-07 | Bristol-Myers Squibb Company | 2-substituted 5-oxazolyl indole compounds useful as IMPDH inhibitors and pharmaceutical compositions comprising same |
US20030229007A1 (en) | 2002-05-30 | 2003-12-11 | Roberto Levi | Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia |
CA2486174A1 (en) | 2002-05-31 | 2003-12-11 | Schering Corporation | Xanthine phosphodiesterase v inhibitor polymorphs |
US20030233118A1 (en) | 2002-06-13 | 2003-12-18 | Hui John C. K. | Method for treating congestive heart failure using external counterpulsation |
US7157100B2 (en) | 2002-06-04 | 2007-01-02 | J.B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical composition for controlled drug delivery system |
US7049333B2 (en) * | 2002-06-04 | 2006-05-23 | Sanofi-Aventis Deutschland Gmbh | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis |
US7763278B2 (en) | 2002-06-10 | 2010-07-27 | Elan Pharma International Ltd. | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
AU2003276648A1 (en) * | 2002-06-17 | 2003-12-31 | Bristol-Myers Squibb Company | Benzodiazepine inhibitors of mitochondial f¿1?f¿0? atp hydrolase and methods of inhibiting f¿1?f¿0? atp hydrolase |
EP1551794A4 (en) * | 2002-06-19 | 2006-05-17 | Bristol Myers Squibb Co | UREIDO-SUBSTITUTED ANILINE COMPOUNDS SUITABLE AS SERINPROTEASE INHIBITORS |
EP1382334A1 (en) | 2002-07-11 | 2004-01-21 | Université de Picardie Jules Verne | Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke |
US20040138306A1 (en) | 2002-07-25 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
ATE458534T1 (de) | 2002-10-04 | 2010-03-15 | Microchips Inc | Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation |
US20040106954A1 (en) | 2002-11-15 | 2004-06-03 | Whitehurst Todd K. | Treatment of congestive heart failure |
US7268157B2 (en) | 2002-11-26 | 2007-09-11 | Shenzhen Chipscreen Biosciences, Ltd. | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity |
-
2005
- 2005-06-02 PL PL05775601T patent/PL1750862T3/pl unknown
- 2005-06-02 DE DE602005025755T patent/DE602005025755D1/de active Active
- 2005-06-02 CA CA2568640A patent/CA2568640C/en not_active Expired - Fee Related
- 2005-06-02 AU AU2005249794A patent/AU2005249794A1/en not_active Abandoned
- 2005-06-02 JP JP2007514218A patent/JP4880591B2/ja not_active Expired - Fee Related
- 2005-06-02 ES ES05775601T patent/ES2282062T1/es active Pending
- 2005-06-02 EP EP05775601A patent/EP1750862B1/en active Active
- 2005-06-02 AT AT05775601T patent/ATE493973T1/de not_active IP Right Cessation
- 2005-06-02 US US11/143,556 patent/US8226977B2/en not_active Expired - Fee Related
- 2005-06-02 WO PCT/IB2005/002689 patent/WO2005118166A2/en not_active Application Discontinuation
-
2006
- 2006-11-30 IL IL179718A patent/IL179718A0/en unknown
-
2011
- 2011-08-19 JP JP2011179762A patent/JP2011252022A/ja not_active Withdrawn
-
2012
- 2012-05-31 US US13/485,493 patent/US8414920B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20120238555A1 (en) | 2012-09-20 |
EP1750862A2 (en) | 2007-02-14 |
AU2005249794A1 (en) | 2005-12-15 |
US8414920B2 (en) | 2013-04-09 |
JP4880591B2 (ja) | 2012-02-22 |
WO2005118166A2 (en) | 2005-12-15 |
CA2568640A1 (en) | 2005-12-15 |
DE602005025755D1 (de) | 2011-02-17 |
ATE493973T1 (de) | 2011-01-15 |
US8226977B2 (en) | 2012-07-24 |
JP2008501680A (ja) | 2008-01-24 |
IL179718A0 (en) | 2007-05-15 |
EP1750862A4 (en) | 2008-06-11 |
US20050271720A1 (en) | 2005-12-08 |
PL1750862T3 (pl) | 2011-06-30 |
CA2568640C (en) | 2011-08-09 |
JP2011252022A (ja) | 2011-12-15 |
EP1750862B1 (en) | 2011-01-05 |
WO2005118166A3 (en) | 2006-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2282062T1 (es) | Composicion farmaceutica que contiene irbesartan. | |
US10786507B2 (en) | Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof | |
US20090186086A1 (en) | Solid multilayer oral dosage forms | |
ES2435240T3 (es) | Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amlodipina, su preparación y su aplicación terapéutica | |
CA2623018A1 (en) | Pharmaceutical compositions of telmisartan | |
KR20130091319A (ko) | 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물 | |
AR061790A1 (es) | Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento | |
JP4509552B2 (ja) | 向上されたバイオアベイラビリティを有する経口医薬組成物 | |
US20180325852A1 (en) | Alditol-free, storage-stable thyroid hormone active drug formulations and methods for their production | |
US20190091204A1 (en) | Compositions of deferasirox | |
US8779000B1 (en) | Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production | |
US20070116759A1 (en) | Pharmaceutical compositions of telmisartan | |
ES2377239T3 (es) | Composiciones farmacéuticas que comprenden irbesartán | |
US20090030052A1 (en) | Pharmaceutical tablet compositions containing irbesartan | |
US8772346B2 (en) | Pharmaceutical composition | |
CN114727955A (zh) | 包含降脂和降血压药物的制剂 | |
TR201918102A1 (tr) | Bi̇r polar çözücüden i̇zole edi̇lmi̇ş amorf dapagli̇flozi̇n i̇çeren kati farmasöti̇k kompozi̇syon | |
ES2262320T3 (es) | Composiciones medicinales de liberacion inmediata para administracion oral. | |
US20060182803A1 (en) | Oral sustained-release pharmaceutical composition of indapamide, production and use thereof | |
BR112014026040B1 (pt) | Comprimido de liberação sustentada que contém levodropropizina | |
RU2005130155A (ru) | Способ получения фармацевтической крмпозиции в виде содержащих фибрат таблеток и таблетки, изготовленные этим способом | |
WO2016054240A1 (en) | Fixed dose combinations for the treatment of viral diseases | |
KR20160054317A (ko) | 로베글리타존을 함유하는 경구 투여용 약제학적 조성물 | |
ES2313578T3 (es) | Formulacion estable que comprende una combinacion de un farmaco sensible a la humedad y un segundo farmaco y procedimiento de preparacion de la misma. | |
RU2799763C2 (ru) | Способ производства фармацевтической композиции, содержащей нефопам и ацетаминофен, и полученная на их основе фармацевтическая композиция |